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Summary
Congenital myasthenic syndrome (CMS) with end-plate
acetylcholinesterase (AChE) deficiency is a rare auto-
somal recessive disease, recently classified as CMS type
Ic (CMS-Ic). It is characterized by onset in childhood,
generalized weakness increased by exertion, refractori-
ness to anticholinesterase drugs, and morphological ab-
normalities of the neuromuscular junctions (NMJs). The
collagen-tailed form of AChE, which is normally con-
centrated at NMJs, is composed of catalytic tetramers
associated with a specific collagen, COLQ. In CMS-Ic
patients, these collagen-tailed forms are often absent.We
studied a large family comprising 11 siblings, 6 of whom
are affected by a mild form of CMS-Ic. The muscles of
the patients contained collagen-tailed AChE. We first
excluded the ACHE gene (7q22) as potential culprit, by
linkage analysis; then we mapped COLQ to chromo-
some 3p24.2. By analyzing 3p24.2 markers located close
to the gene, we found that the six affected patients were
homozygous for an interval of 14 cM between D3S1597
and D3S2338. We determined the COLQ coding se-
quence and found that the patients present a homozy-
gous missense mutation, Y431S, in the conserved C-
terminal domain of COLQ. This mutation is thought to
disturb the attachment of collagen-tailed AChE to the
NMJ, thus constituting the first genetic defect causing
CMS-Ic.
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Introduction
The congenital myasthenic syndromes (CMSs) are a het-
erogeneous group of diseases caused by genetic defects
affecting neuromuscular transmission. They are char-
acterized by weakness and abnormal fatigability on ex-
ertion and, in the majority of cases, occur during the
first 2 years of life (Bundey 1972; Fenichel 1978). An
international workshop supported by the European
Neuro Muscular Consortium (ENMC) has classified the
CMSs (Middleton 1996) on the basis of their genetic
and clinical features. CMS type I corresponds to the
autosomal recessive forms: type Ia corresponds to fa-
milial infantile myasthenia (MIM 254210), type Ib to
limb-girdle myasthenia (MIM 159400), type Ic to ace-
tylcholinesterase (AChE) deficiency, and type Id to
acetylcholine receptor deficiency. CMS type II is the au-
tosomal dominant “classic slow channel syndrome”
(MIM 601462), which is caused by mutations in the
alpha (MIM 100690) or epsilon (MIM 100725) subunits
of the acetylcholine receptor.
The CMS-Ic with end-plate AChE deficiency was first
described by Engel et al. (1977). It is characterized by
onset during childhood, generalized weakness increased
by exertion, refractoriness to anticholinesterase drugs,
decremental electromyographic response, and morpho-
logical abnormalities of the neuromuscular junctions
(NMJs) (Engel 1994).
NMJs normally possess a high concentration of col-
lagen-tailed AChE forms, also called “asymmetric,” or
“A,” forms (Massoulie´ et al. 1993), which may be re-
moved from NMJs by collagenase treatment (Hall and
Kelly 1971; Hall 1973). The A4, A8, and A12 forms
are defined by the attachment of one, two, and three
AChE tetramers, respectively, to the homotrimeric col-
lagen COLQ (Krejci et al. 1997) via a short proline-rich
attachment domain (PRAD) (Bon et al. 1997).
Most of the CMS-Ic patients described so far have
shown a marked decrease in total muscle AChE, with
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Figure 1 Morphological and biochemical characterization of NMJs in a CMS-1c patient (II-8). a, Sedimentation profiles of AChE in the
HSS muscle extract, which revealed the presence of AChE A forms, with a normal sensitivity to collagenase. The sedimentation coefficients
were deduced from the position of internal marker proteins, E. coli b-galactosidase (16 S) and alkaline phosphatase (6.1 S). b, Histochemical
staining of AChE activity at end plates, by the method of Koelle and Friedenwald (1949), which required prolonged incubation (4 h, instead
of the 10 min required for normal muscle). In contrast, the density of receptors appeared normal with fluorescein-conjugated a-bungarotoxin
(not shown). Both methods showed that the end plates were abnormally small (#600). c, Silver impregnation of nerve terminals on muscle
sections, which showed a normal aspect of the terminal-nerve arborization in the end-plate region (#600). d, Electron microscopy of nerve
terminals (n), which appeared to be slightly reduced in size and partly surrounded by Schwann-cell processes (arrows), with an apparently
normal content of synaptic vesicles. The junctional folds showed marked degenerative changes (asterisks [*]). Focal myofibrillar alterations with
streaming of the Z lines were seen in the adjacent muscle fibers (#7,100).
essentially no collagen-tailed forms (Engel et al. 1977;
Jennekens et al. 1992; Hutchinson et al. 1993). Nev-
ertheless, one case with a detectable level of collagen-
tailed forms has been reported (Hutchinson et al. 1993).
We here report the analysis of a family with 11 sib-
lings, 6 of whom are affected with a mild form of CMS-
Ic. Since childhood, these patients have presented limb
weakness and fatigability and single-motor-nerve stim-
ulation–evoked repetitive responses. Analysis of biopsies
from two patients revealed that AChE activity at the end
plates was abnormally low but that the muscle contained
collagen-tailed forms.
Two genes appeared as potential candidates for this
disease: ACHE (MIM 100740), the AChE gene, located
at 7q22 (Ehrlich et al. 1992; Getman et al. 1992), which
encodes the catalytic subunits of all molecular species of
AChE, and COLQ, which encodes the collagen tail of
asymmetric forms. In light of the presence of collagen-
tailed forms of AChE in the patients’ muscles, nonsense
mutations and missense mutations were unexpected in
these genes’ regions directly involved in the formation
of the asymmetric forms, but mutations at other sites
could not be excluded. We therefore cloned the human
COLQ gene and determined its genetic localization.
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Figure 2 Pedigree of family 1605. Affected individuals are represented by black dots (for females) and black squares (for males), and
unaffected individuals are represented by unblackened circles (for females) and unblackened squares (for males). A diagonal slash through a
symbol denotes that the individual is deceased. The haplotypes of chromosome 3p24.2 microsatellite markers are shown below each individual.
Table 1
Pairwise LOD Scores between CMS-1c and Chromosome 3p24.2
Markers, for Family 1605
MARKER
LOD SCORE AT RECOMBINATION FRACTION OF
.00 .01 .05 .10 .20 .30 .40
D3S1597 4.86 2.08 .78 .31 .01 .09 .07
D3S3589 2.15 2.11 1.95 1.74 1.31 .86 .40
D3S1263 4.39 4.31 3.96 3.51 2.61 1.69 .77
D3S1259 4.48 4.39 4.04 3.59 2.68 1.75 .81
D3S3701 1.83 1.80 1.66 1.49 1.12 .74 .34
D3S3610 2.97 2.90 2.63 2.30 1.68 1.08 .50
D3S1585 1.90 1.87 1.73 1.55 1.17 .77 .36
D3S1554 1.83 1.8 1.66 1.49 1.12 .74 .34
D3S3608 3.14 3.07 2.79 2.44 1.79 1.16 .55
D3S3473 2.11 2.07 1.91 1.71 1.28 .84 .39
D3S3595 2.77 2.71 2.45 2.15 1.56 1.00 .44
D3S1286 4.49 4.40 4.05 3.60 2.69 1.76 .82
D3S2338 2.56 .15 1.00 1.26 1.18 .77 .26
D3S1293 3.87 1.26 .60 .34 .13 .04 .01
Taking advantage of the informativity of the family, we
determined the potential involvement of these two genes,
by linkage analysis. We found a significant linkage to
COLQ, and we then identified a first mutation that is
likely to cause CMS-Ic.
Patients and Methods
Patients
We analyzed 11 siblings, ages 36–61 years, from a
Spanish family (fig. 1); 6 of them (4 males and 2 females
[ages 43–61 years]) were affected with a mild form of
CMS-Ic, diagnosed on the basis of the ENMC interna-
tional workshop criteria (Middleton 1996). The parents
were asymptomatic. Blood samples and muscle biopsies
were taken after informed consent was obtained. The
onset of the myasthenic symptoms occurred at age 6–10
years in all the patients, who complained of great fati-
gatibility on exertion, mainly during the 2d decade of
life. Two of them presented permanent neck and upper-
limb weakness (patient II-8) or diffuse weakness (patient
II-9). Electrophysiological studies performed on
four patients (patients II-5, II-8, II-9, and II-12) revealed
impaired muscle-nerve conduction, with decremental re-
sponses at 3 Hz, repetitive responses to single-motor-
nerve stimulation, and abnormal jitter. A discrete ptosis
and a mild myopathic syndrome were present only in
patient II-9. None of the patients had slowed pupil mo-
tricity, respiratory distress, or bulbar symptoms. No
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Figure 3 Alignment of human, rat, and Torpedo amino acid
sequences of AChE-associated collagen, COLQ. Identical amino acids
are denoted by asterisks (*). The hatched box represents the proline-
rich attachment domain (PRAD), gray-shaded boxes represent the pu-
tative heparan sulfate proteoglycan-binding domains, and the left-fac-
ing herringbone symbols (!!!) denote the collagen triple-helical do-
main, which contains 63 triplets of Gxy in human COLQ. The 15
conserved cysteines are denoted by a blackened diamonds: C51 and
C52 in PRAD, which establish disulfide bonds with AChE subunits;
C291 and C293, which probably are involved in bonds between the
three collagen chains; and the 10 cysteines of the C-terminal domain.
The mutated tyrosine is boxed.
anti-AChR antibody was detected, and parenteral ad-
ministration of anticholinesterase drugs had either no
beneficial or even a worsening effect.
Morphological Analyses
Muscle biopsies were taken from the deltoid muscle,
in the end-plate region (patients II-8 and II-9). Cryostat
sections of muscle biopsies, taken by means of routine
histochemical methods, showed both marked predomi-
nance of type I fibers and atrophy of type II fibers. Stain-
ing of AChE (Koelle and Friedenwald 1949) and labeling
of receptors with fluorescein-conjugateda-bungarotoxin
showed very small end plates with a reduced subneural
apparatus, both on unfixed or on glutaraldehyde-fixed
teased muscle fibers. Muscle sections were treated for
silver impregnation of the nerve terminals, according to
the Gros-Bielchowsky method (Gros and Schultze 1918).
Electron microscopy of end plates was performed by
conventional methods.
Biochemical Analysis
AChE was extracted from muscle biopsies (∼20 mg),
in two steps (Bon et al. 1978). The detergent-soluble
fraction (DS) was extracted after both incubation with
650 ml of detergent buffer (10 mM Tris pH 7.0, 50 mM
MgCl2, 1% Triton X-100) with antiproteolitic (2 mM
benzamidine, 2 mg bacitracine/ml) and centrifugation
for 30 min at 15,000 g and 4C. The pellet was then
resuspended in the same buffer, containing 1 M NaCl
to extract the high salt–soluble fraction (HSS). AChE
molecular forms were analyzed in 5%–20% sucrose gra-
dients in the same buffers. Approximately 45 fractions
were collected after centrifugation (16 h at 35,000 g in
a Beckman SW41 rotor) and were assayed for AChE
activity, by the method of Ellman et al. (1961).
The DS extract, corresponding to ∼75% of the sol-
ubilized activity, contained exclusively globular forms,
and the HSS extract, corresponding to ∼25% of solu-
bilized activity, contained a significant proportion of A
forms, as in the case of normal controls (Carson et al.
1979). Sensitivity to collagenase was studied after in-
cubation of the AChE extracts with 0.01 v of collagenase
ABC form III from Clostridium histologicum (Advance
Biofacture) in 50 mM Tris-HCl pH 8.0 at 25C.
Radiation-Hybrid Mapping
The GeneBridge 4 radiation-hybrid panel (Research
Genetics) and the following specific intronic primers
were used to amplify a 315-bp human COLQ DNA
fragment, with TCC TGT AAG TAA TGC TAC CAC
TGG and TGT TAG ATG TGG ATA GGC CTC C (5′
to 3′), 35 PCR cycles (30 s at 94C, 30 s at 56C, and
30 s at 72C), and “hot start.” The products were an-
alyzed by 1.5% agarose gel electrophoresis. The LOD-
score calculations were processed by the program
RHMAPPER on the Whitehead Institute/MIT center
server, with 15 as the LOD score required for demon-
stration of linkage (Slonim et al. 1997).
Genotyping
DNA was prepared from blood by means of standard
protocols. (CA)n microsatellite markers were provided
by the Ge´ne´thon human genetic-linkage maps (Dib et
al. 1996). Several amplification products from the same
DNA sample (80 ng) (Helbling-Leclerc et al. 1995), gen-
erated with different primer sets, were pooled and an-
alyzed in a single lane of a 6% denaturating polyacryl-
amide gel. After they were transferred to Hybond N
membranes (Amersham), hybridization was performed
with a poly(CA) probe.
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Figure 4 Identification of the Y431S mutation. a, SSCP analysis of PCR products from genomic DNA in 10% polyacrylamide gel, for a
control individual (lane C) showing normal migration pattern (unblackened arrows), affected individuals (blackened symbols) showing a mutant
pattern with three characteristic bands (blackened arrows), and nonaffected members of the family, displaying fused patterns of mutated and
normal alleles (six bands). b–d, Detection of a homozygous missense mutation, Y431S, by direct sequencing. Genomic DNA samples were
amplified with the primer pair CT3L-CT3R; partial COLQ sequences of a healthy control (b), an affected individual (c), and a heterozygous
nonaffected individual (d) are shown. The patients present a homozygous ArC substitution at position 1292, which replaces tyrosine 431 by
a serine in the C-terminal region of COLQ. Nucleotides are numbered beginning from the ATG of the cDNA sequence.
Linkage Analysis
Linkage analysis was performed by MLINK (LINK-
AGE version 5.2 package), under the assumption of au-
tosomal recessive inheritance and a partial penetrance,
with four arbitrary liability classes: age 0–10 years, age
10–20 years, age 20–40 years, and age 140 years, with
penetrances of .40, .60, .80, and .95 respectively. We
assumed a disease gene frequency of .001 and equal
female and male recombination rates.
Human COLQ Sequence
We screened a human DNA cosmid library with a rat
cDNA fragment (891–1420 of rQ1; Genbank accession
number AF007583). We mapped and sequenced a ge-
nomic fragment containing the exon that encodes the
PRAD. We defined PCR primers in this exon and in the
C-terminal domain from a human EST, H93653, which
was identified, by a Blast search in databanks, on the
basis of homology to rat and Torpedo ColQ sequences.
Using this pair of primers, we amplified a large part of
the human COLQ coding sequence, both from skeletal
muscle biopsies and from lymphoblastoid cell lines. The
5′ part of the cDNA was obtained by 5′ RACE
(GibcoBRL, reference number 18374-058) and direct se-
quencing. We determined the exon-intron organization
of the C-terminal noncollagenous domain, by direct se-
quencing of the cosmid.
SSCP Analysis and Direct Sequencing of PCR Products
SSCP analysis and sequencing of the PCR products
were performed as described elsewhere (Helbling-Leclerc
et al. 1995). Primers were designed to amplify the 5′
COLQ coding sequence from cDNA obtained by reverse
transcription (First-Strand cDNA synthesis kit; Phar-
macia) of total mRNA prepared from lymphoblastoid
cell lines (RNA Plus; Bioprobe Systems). cDNA am-
plification required two successive PCRs. The four exons
(CT1–CT4) encoding the C-terminal noncollagenous
domain were amplified from genomic DNA, with flank-
ing intronic primers. The primers used to amplify exon
CT3 were CT3L (5′-ATC CCT TGG GCC GCA TGG
T) and CT3R (5′-GCA GGG AGC ACG TGT TGT).
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Figure 5 Schematic representation of the association of tetra-
meric AChE subunits with collagen Q subunits in the collagen-tailed
A12 form of AChE. The location of the mutation is indicated by the
arrow
Results
Morphological and Biochemical Analyses
Morphological and biochemical analyses were per-
formed in biopsies of deltoid muscles obtained from pa-
tients II-8 and II-9. Histochemical staining revealed that
the AChE activity at the end plates was abnormally low,
detectable only after several hours of incubation (fig. 1b),
whereas the density of receptors appeared normal (not
shown); in addition, the end plates were much smaller
than those in control muscles (fig. 1b). Electron mi-
croscopy demonstrated that the nerve terminals of the
muscles in one of these patients covered only a fraction
of the postsynaptic region (fig. 1d). The collagen-tailed
forms of AChE—the A12 and A8 forms, which sediment
at 16 and 14 S, respectively—were present and, in their
sedimentation coefficient and sensitivity to collagenase
(Carson et al. 1979) (fig. 1a), as well as in their aggre-
gation at low ionic strength (not shown), appeared to
be identical to those of normal muscle.
Linkage Analysis
Three microsatellite markers—D7S2509, D7S2453,
and D7S501—located close to ACHE (Collins et al.
1996) were analyzed in all family members; the signif-
icant negative LOD scores of12.38,9.83 and9.83,
respectively, at a recombination fraction of 0 excluded
a defect in the ACHE gene. We therefore examined a
potential linkage of the disease with COLQ. To localize
the human gene, we screened a human cosmid library
with a rat colQ cDNA probe (Krejci et al. 1997), per-
mitting us to identify and partly sequence a restriction
fragment containing the PRAD coding exon.
Using primers derived from this fragment, we mapped
the gene on chromosome 3p24.2, between the poly-
morphic markers D3S1263 and D3S1583, which are
separated by a genetic distance of 16 cM. We analyzed
12 microsatellite markers located between these markers
and 2 microsatellite markers above D3S1263 (fig. 2).
Eleven of these markers were homozygous for the six
affected patients (table 1). The deduced at-risk haplotype
of the deceased mother happened to be identical to that
of the father, suggesting consanguinity. This was not ver-
ified; but it would not be surprising, since the parents
originated from neighboring villages in Spanish Cata-
lonia. Among the unaffected children, three received the
at-risk haplotype from the father and two received it
from the mother, making them all heterozygous carriers
of the genetic defect (fig. 2). These results indicated that
the genetic defect causing the disease in this family was
located in a 14-cM interval between D3S1597 and
D3S2338. This defect was therefore likely to reside in
COLQ.
COLQ Sequence
We determined the cDNA sequence of COLQ (EMBL
accession number AJ225895). It contains 119 nucleo-
tides of the 5′ UTR and 377 nucleotides of the 3′ UTR.
The coding sequence (positions 120–1490) is highly ho-
mologous to those of rat and Torpedo. Human and rat
present 89% identity both at the nucleotide level and at
the amino acid level, whereas human and Torpedo show
64% identity at the nucleotide level and 58% identity
at the amino acid level. Alignment of the three deduced
peptide sequences shows that nonconserved regions al-
ternate with remarkably well conserved regions, which
define potentially functional domains (fig. 3).
Detection of the Mutation
We screened the COLQ coding sequence by PCR-
SSCP on transcripts from patients’ lymphoblastoid cell
lines and genomic DNA. The only abnormal SSCP con-
formers were found in the CT3 exon and cosegregated
with the at-risk haplotype (fig. 4). By direct sequencing,
we observed an ArC transversion at position 1292, re-
placing tyrosine 431 (TAT) by a serine (TCT). We did
not find this SSCP conformer in 150 unrelated healthy
individuals, suggesting that it does reflect a pathological
variation.
Discussion
CMS type Ic is a rare recessive disease, with only six
cases reported prior to the present study (Engel et al.
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1977; Jennekens et al. 1992; Hutchinson et al. 1993).
It is characterized by abnormally low AChE activity in
muscles, a reduction of the end-plate size, and abnormal
nerve terminals covering only a fraction of the postsy-
naptic region. In five of these six cases, the collagen-
tailed forms of AChE were absent. Indeed, the normal
end-plate innervation is probably modulated locally by
the AChE activity, since, in CMS-Ic patients, a reduction
of end plates was observed, whereas in transgenicXeno-
pus, AChE overexpression promoted neurite outgrowth
(Sternfeld et al. 1998).
In the large CMS-Ic family that we have described
here, the patients presented not only both a decremental
response to repetitive nerve stimulation and repetitive
responses evoked by single nerve stimuli, suggesting lack
of accumulation of AChE, but also small end plates,
abnormal encasement of the presynaptic membrane by
Schwann cells, and degeneration of junctional folds, as
has been shown elsewhere by electronic microscopy in
other CMS-Ic patients (Engel et al. 1977). Nevertheless,
biochemical analyses showed the presence of a normal
complement of A12 and A8 forms, which, in their sed-
imentation coefficient, sensitivity to collagenase, and ag-
gregation at low ionic strength, appeared to be identical
to those of normal muscle. These patients presented a
mild form of the disease, with 6–10 years, instead of
0–2 years, being the age at onset of symptoms, no
ophthalmoplegia, and normal pupillary response to
light. This delay may be related to modifications of the
anchoring of A forms in the NMJ during development.
Alternatively, the lack of accumulation of AChE may
exert its effect only after a long period. This latter option
is supported by the late onset of neuromotor deficiencies
in transgenic mice with overexpressed AChE (Andres et
al. 1997).
Prior to the present study, the involvement of the
AChE gene had been investigated in several CMS-Ic pa-
tients with a deficiency in collagen-tailed forms of AChE
at the NMJs. This investigation had been performed by
means of sequence analysis of the exons that encode the
AChE domain to which the tail subunit binds, by South-
ern analysis of ACHE (Hutchinson et al. 1993; Camp
et al. 1995) and by a functional approach that investi-
gated the association of the patient enzyme with a for-
eign tail collagen (Camp et al. 1995). No difference has
been found between patients and controls. Since the end
plates of the patients in the previous studies lacked the
characteristic collagen-tailed forms of AChE, which are
associated with the basal lamina, it has been suggested
that the defect might reside in either an alteration in a
protein involved in promoting the assembly between the
catalytic and tail subunits or an altered structure of the
tail subunit (Camp et al. 1995). The first hypothesis is
not consistent with the fact that coexpression of AChE
and ColQ is sufficient to provide oligomerization of col-
lagen-tailed forms in several cell lines (Coussen et al.
1995) and in Xenopus oocytes (Krejci et al. 1997). In
the present study, we first definitively excluded the AChE
gene as a potential culprit by means of linkage analysis;
then we analyzed the second hypothesis—the potential
involvement of the COLQ gene. For this purpose, we
localized the human gene on chromosome 3p24.2 and
analyzed polymorphic microsatellite markers flanking
the gene in all members of the family. We thus found
that all patients are homozygous for the genetic interval
encompassing COLQ. We cloned the human gene and
determined the presence of a homozygous sequence var-
iation inducing an amino acid substitution in the pa-
tients, which was not found in 300 normal chromosomes
even in the heterozygous state. The missense mutation,
Y431S, identified in the homozygous state in the six
patients and in the heterozygous state in all the unaf-
fected members of the family, changes one of the last
amino acids of COLQ.
The protein comprises distinct regions: the N-terminal
domain contains the highly conserved PRAD, which
binds AChE tetramers (Bon et al. 1997); the central part
of the protein is the collagen domain, with its 63 typical
Gxy triplets, which participates in the formation of the
homotrimeric collagen; and the C-terminal domain con-
tains three conserved regions. The second conserved re-
gion plays a role in homotrimeric collagen formation
(Krejci et al. 1997), whereas the third conserved region
contains nine conserved cysteines, although their exact
function is not known. The localization of the mutation
in the third conserved region of the C-terminal domain
(fig. 5) is consistent with the fact that it does not affect
either the formation of the collagen-tailed forms or their
sensitivity to collagenase. Ionic interactions of these mol-
ecules with polyanionic proteoglycans are currently as-
sumed to be the primary cause for the clustering of AChE
in the specialized basal lamina of the NMJ (Bon et al.
1978; Brandan et al. 1985; Rotundo et al. 1997). It has
been suggested that these ionic interactions involve two
heparin-binding sites, located within the collagen triple-
helical region of COLQ (Deprez and Inestrosa 1995)
(fig. 2). These sites are not modified by the present mu-
tation, a finding that is in agreement with the normal
low salt aggregation of AChE A forms from the patient
muscles. Therefore, it appears that the Y431S mutation
affects a still unrecognized—but critical—interaction,
possibly with a receptor site located either in the extra-
cellular matrix or in the postsynaptic membrane.
Various COLQ mutations, missense as nonsense, may
compromise several steps of the oligomerization of the
A forms or their anchoring in the NMJ and thereby may
generate more or less severe pathologies. The most severe
forms are associated with a marked decrease in total
muscle AChE (Engel et al. 1977; Jennekens et al. 1992;
Hutchinson et al. 1993), with essentially no collagen-
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tailed forms, but the patients still possess normal levels
of globular AChE forms in their erythrocytes (Hutch-
inson et al. 1993). These pathologies may be caused
either by nonsense mutations in the N-terminal part of
COLQ or mutations in the PRAD, which would prevent
AChE attachment of an AChE tetramer. Mutations in
the collagen domain or in the second conserved C-ter-
minal region may also prevent a normal formation of
homotrimeric collagen.
In the present article, we have described a family as-
sociated with a mild form of CMS-Ic and have reported
that the disease is caused by a mutation in the C-terminal
part of COLQ. This is the first demonstration of a causal
relationship between COLQ mutation and CMS-Ic.
Analysis of genes encoding COLQ or interacting pro-
teins in other patients should contribute to elucidation
of the molecular basis of human CMS-Ic.
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